CITIC Securities has released a research report highlighting the potential of RAS-targeted therapies in oncology. These therapies aim to unlock previously undruggable targets within the RAS gene family, which includes KRAS, NRAS, and HRAS, with KRAS being particularly significant in human cancers. The field is advancing beyond single-point mutations like KRAS G12C to address broader targets such as G12D, Pan-KRAS, and Pan-RAS(ON), with numerous companies actively pursuing these avenues. AI
RANK_REASON Research report from a financial institution detailing advancements in cancer therapy targets. [lever_c_demoted from research: ic=1 ai=0.1]
- American Society of Clinical Oncology
- CITIC Securities
- HRAS
- KRAS
- KRAS G12C
- KRAS G12D
- NRAS
- Pan-KRAS
- Pan-RAS
AI-generated summary · Google Gemini · from 1 sources. How we write summaries →
